my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
25-01-2012: MorphoSys AG announced that the US Patent and Trademark Office (USPTO) has granted a patent covering the Company's cancer compound MOR202. The new patent (US 8,088,896) covers MorphoSys's HuCAL antibody against CD38 as well as pharmaceutical compositions comprising the same, and has a scheduled expiry date in 2028, not including any potential regulatory extensions.
"In 2011, MOR202 became our third proprietary antibody program in clinical trials, following MOR103 in rheumatoid arthritis and multiple sclerosis and MOR208 in chronic lymphocytic leukemia," commented Dr. Marlies Sproll, Chief Scientific Officer of MorphoSys AG. "Strengthening our intellectual property position on our proprietary products, particularly in our most important markets Europe, the USA and Asia, is of high priority for MorphoSys."
MOR202 is a fully human HuCAL antibody directed against CD38, a therapeutic target for the treatment of multiple myeloma and certain forms of leukemia. The HuCAL-derived, fully human antibody is currently being tested in a phase 1/2a trial in patients with relapsed/refractory myeloma.
Contact / Request information
Request further information free of charge:
Watchlist
This is where you can add this news to your personal favourites
MorphoSys Nominates Karin Eastham and Marc Cluzel as New Supervisory Board Members
MorphoSys AG announced that the Company will nominate Ms. Karin Eastham and Dr. Marc Cluzel as new members of the Supervisory Board at the Company's Annual Shareholder Meeting on Thursday, May 31, 2012. Ms. Eastham and Dr. Cluzel will replace Prof. Dr. Jürgen Drews and Dr. Metin Colpan. Pro ... more
MorphoSys Strengthens Patent Position on MOR202 Program
MorphoSys AG announced that the US Patent and Trademark Office (USPTO) has granted a patent covering the Company's cancer compound MOR202. The new patent (US 8,088,896) covers MorphoSys's HuCAL antibody against CD38 as well as pharmaceutical compositions comprising the same, and has a sched ... more
MorphoSys Initiates Phase 1b Clinical Trial with MOR103 in Patients with Multiple Sclerosis
MorphoSys AG announced that a phase 1b clinical trial evaluating MOR103, a human monoclonal antibody to GM-CSF (granulocyte macrophage-colony stimulating factor), in patients with multiple sclerosis (MS) is now open for enrollment, thereby adding a second indication to the development progr ... more
Leader Laboratory Mammalian Antibody Production (m/f)
As one of the leading public biotech companies in Europe, we are committed to developing the medicines of the future. Building on our portfolio of innovative antibody technologies, we are actively pursuing new therapeutic approaches in close collaboration with the world‘s foremost pharmaceu ... more
MorphoSys AG, located in Martinsried/Munich, is one of the worlds leading biotechnology companies focusing on fully human antibodies. With its unique technologies, MorphoSys is developing the next generation of therapeutic antibodies which can be used not only for research and diagnostics b ... more
PBL awarded two US patents on RNAi
Plant Bioscience Limited (PBL) announced that the United States Patent and Trademark Office (USPTO) has issued out US Patent No. 8,258,285 with fundamental claims directed to compositions to effect gene silencing and US Patent No. 8,263,569 with fundamental claims directed to methods of ind ... more
US Patent Granted for Verona Pharma’s RPL554
Verona Pharma plc announced that the United States Patent and Trademark Office has granted a new patent for the Company’s lead drug candidate, RPL554. The patent is the fourth patent issued for RPL554 and related compounds in the US.RPL554, Verona Pharma's lead drug candidate, is a dual pho ... more
New Patents Issued to Diffusion Pharmaceuticals
Diffusion Pharmaceuticals LLC announced that the U.S. Patent and Trademark Office has granted it patent numbers 7919527 and 8030350, entitled “Bipolar Trans Carotenoids Salts and Their Uses” and “Trans Carotenoids, Their Synthesis and Uses,” respectively. These patents include compound, com ... more
U.S. Patent & Trademark Office (USPTO)
The United States Patent and Trademark Office (USPTO) is the Federal agency for granting U.S. patents and registering trademarks. In doing this, the USPTO fulfills the mandate of Article I, Section 8, Clause 8, of the Constitution that the Executive branch "promote the progress of science a ... more
Über CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2013 CHEMIE.DE Information Service GmbH, All rights reserved
Netmeeting
